J
Juergen Foell
Researcher at National and Kapodistrian University of Athens
Publications - 6
Citations - 582
Juergen Foell is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Progenitor cell & Thalassemia. The author has an hindex of 3, co-authored 6 publications receiving 244 citations.
Papers
More filters
Journal ArticleDOI
CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia
Haydar Frangoul,David Altshuler,M. Domenica Cappellini,Yi-Shan Chen,Jennifer Domm,Brenda K. Eustace,Juergen Foell,la Fuente Josu de,Stephan A. Grupp,Rupert Handgretinger,Tony W. Ho,Antonis Kattamis,Andrew Kernytsky,Julie A. Lekstrom-Himes,Amanda M. Li,Franco Locatelli,Markus Y. Mapara,Montalembert Mariane de,Damiano Rondelli,Akshay Sharma,Sujit Sheth,Sandeep Soni,Martin H. Steinberg,Donna A. Wall,Angela Yen,Selim Corbacioglu +25 more
Journal ArticleDOI
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Haydar Frangoul,David Altshuler,M. Domenica Cappellini,Yi-Shan Chen,Jennifer Domm,Brenda K. Eustace,Juergen Foell,Josu de la Fuente,Stephan A. Grupp,Rupert Handgretinger,Tony W. Ho,Antonis Kattamis,Andrew Kernytsky,Julie A. Lekstrom-Himes,Amanda M. Li,Franco Locatelli,Markus Y. Mapara,Mariane de Montalembert,Damiano Rondelli,Akshay Sharma,Sujit Sheth,Sandeep Soni,Martin H. Steinberg,Donna A. Wall,Angela Yen,Selim Corbacioglu +25 more
TL;DR: Electroporation of CD34+ hematopoietic stem and progenitor cells obtained from healthy donors was performed, with CRISPR-Cas9 targeting the BCL11A erythroid-specific enhancer, and approximately 80% of the alleles at this locus were modified, with no evidence of off-target editing.
Journal ArticleDOI
Haploidentical CD3 or α/β T-cell depleted HSCT in advanced stage sickle cell disease
Juergen Foell,Johannes H. Schulte,Beatrix Pfirstinger,Anja Troeger,Daniel Wolff,Matthias Edinger,Petra Hofmann,Charalampos Aslanidis,Peter Lang,Ernst Holler,Angelika Eggert,Selim Corbacioglu +11 more
TL;DR: The results demonstrate the feasibility, safety, and efficacy of T-haplo-HSCT also for adult advanced stage SCD patients.
Journal ArticleDOI
Haploidentical stem cell transplantation with CD3+-/CD19+- depleted peripheral stem cells for patients with advanced stage sickle cell disease and no alternative donor: results of a pilot study.
TL;DR: Haploidentical stem cell transplantation with CD3 + -/CD19 + - depleted peripheral stem cells for patients with advanced stage sickle cell disease and no alternative donor and results of a pilot study.
Journal ArticleDOI
Alternative donor: αß/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease
TL;DR: The results are encouraging and demonstrate the feasibility, safety, and efficacy of T-haplo-HSCT in advanced stage SCD in children and adults, thus offering a curative alternative to majority of patients.